Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

542
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
542
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

6.2K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
6.2K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

4.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.8K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

868
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
868

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

It's time to test all adults for lipoprotein(a).

Journal of clinical lipidology·2026
Same author

Lipoprotein(a) and Women's Cardiovascular Health: A Review.

JACC. Advances·2026
Same author

Addressing the Lp(a) hypothesis: will lowering Lp(a) decrease the risk of cardiovascular events?

Nature reviews. Cardiology·2026
Same author

Cytosine base editing of LPA in transgenic mice averts large deletions.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Clinical Care for Patients With Elevated Lipoprotein(a) Level in Canada: A Practical Framework for Screening, Risk Assessment, and Management.

The Canadian journal of cardiology·2026
Same author

Lipoprotein(a): An Underappreciated Inherited Risk Factor for Atherosclerosis, Aortic Stenosis, and Abdominal Aortic Aneurysm.

Annual review of medicine·2025

Related Experiment Video

Updated: Jan 12, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.7K

Evolving guidelines on lipoprotein(a).

Michael B Boffa1,2, Marlys L Koschinsky1,3, Robert A Hegele1,2,4

  • 1Robarts Research Institute.

Current Opinion in Lipidology
|November 5, 2025
PubMed
Summary

Elevated lipoprotein(a) [Lp(a)] is a key risk for cardiovascular disease. Guidelines now suggest universal Lp(a) screening and incorporating levels into prevention strategies, though more research is needed.

Keywords:
atherosclerotic cardiovascular diseaseclinical guidelineslipoprotein(a)preventive cardiology

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.3K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Related Experiment Videos

Last Updated: Jan 12, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.7K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.3K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Area of Science:

  • Cardiology
  • Atherosclerosis Research
  • Lipidology

Background:

  • Elevated plasma lipoprotein(a) [Lp(a)] is a recognized causal risk factor for atherosclerotic cardiovascular disease.
  • Lp(a) has emerged as a significant therapeutic target in cardiovascular risk management.

Purpose of the Study:

  • To review the evolution of scientific statements and clinical guidelines concerning Lp(a) over the past 15 years.
  • To track changes in recommendations for Lp(a) management and screening.

Main Methods:

  • Systematic review of global medical body statements and clinical guidelines published over the last 15 years.
  • Analysis of evolving recommendations regarding Lp(a) levels and cardiovascular disease risk.

Main Results:

  • Studies increasingly demonstrate Lp(a)'s independent association with cardiovascular disease, enabling refined risk stratification.
  • Guidelines now advocate for universal Lp(a) screening and consider it a risk-enhancing factor in primary prevention.
  • Gaps and inconsistencies in current recommendations persist despite growing evidence.

Conclusions:

  • Consensus is growing for routine Lp(a) measurement in all adults and its integration into cardiovascular disease prevention decision-making.
  • Future cardiovascular outcomes trials of Lp(a)-lowering therapies will shape clinical practice.
  • Caution is advised due to remaining gaps in the evidence base supporting current consensus.